The mechanism: The Inflation Reduction Act doesn't hit every blockbuster drug at once — it hits by launch date, moving down a clock that starts ticking the moment a small-molecule drug has been on the market nine years (or a biologic thirteen). Semaglutide, first approved as Ozempic in 2017, aged into eligibility on schedule: CMS already selected the full semaglutide family — Ozempic, Wegovy, and Rybelsus — for its second negotiation round, with negotiated Medicare prices (roughly $274/month, a 71% cut from list) taking effect January 2027. Tirzepatide, approved in 2022 as Mounjaro and 2023 as Zepbound, is younger by law. It isn't projected to reach a negotiation cycle until 2028 or 2029 at the earliest. Any legislative push to compress that IRA calendar — a bipartisan favorite pre-election — closes the gap for Lilly's newer franchise while doing nothing to un-negotiate Novo's price, which is already cemented. Novo eats the cut years before Lilly's flagship growth drug even enters the room.

Who cashes in:

  • LLY — Tirzepatide's Medicare-negotiation clock effectively resets later than semaglutide's regardless of how fast Congress moves, because eligibility is date-of-approval driven. Every quarter that passes, Lilly banks unnegotiated Part D and commercial pricing on Mounjaro/Zepbound while Novo's core franchise is already discounted. Lilly's newer oral and next-gen obesity pipeline (orforglipron, retatrutide) buys even more runway before any of it sees a negotiation table.
  • VKTX — Viking's amylin/GLP-1 candidates are pre-approval, meaning they sit completely outside the IRA's negotiation math for a decade-plus once launched. A faster-negotiation political climate makes late-to-market, patent-fresh obesity assets structurally more valuable relative to first-movers now facing price compression — Viking is a direct beneficiary of that repricing of "when you launched matters more than what you launched."
  • MRK, BMY, ABBV — None have first-generation GLP-1 exposure aging toward negotiation; each carries newer immunology/oncology franchises with later eligibility clocks, insulating them from this specific catalyst while Novo absorbs headline risk.